SPONSORED

With Pending FDA Approval(12) and Growing Medical Leaf Support, Rapid Therapeutic Science Laboratories Could Be One of 2021’s Top Companies

U.S. OTC: (RTSL)

News Update June 8, 2021:
Rapid Therapeutics Prepares to Bring Sublingual Spray Products to Market

The Top Reasons to Have Rapid Therapeutic Science Laboratories U.S. OTC: (RTSL) On Your Radar

  1. Rapid Therapeutic Science Laboratories U.S. OTC: (RTSL) looks well-positioned in a medical leaf market expected to balloon to $35.1 billion in the next five years.(1)
  2. Its products deliver measured amounts of cann-a-bi-noids straight to the systemic blood system through the lungs with a short burst of aerosolized medicine.(2)
  3. Its Rxoid Metered Dose Inhaler is 98% bioavailable.(2)
  4. Compared to edibles, a 5mg dose from a Rxoid MDI is approximately 2,000% more efficient in delivering leaf into the bloodstream.(3)
  5. With more states legalizing the use of green leaf, and speculation of legalization at the federal level, there’s growing excitement.(4)

Rapid Therapeutic Science Laboratories U.S. OTC: (RTSL) is racing to meet medical leaf demand for millions of users. With its metered dose inhaler that delivers cannab-inoids straight to the systemic blood system, its product could provide up to 98% bioavailability.

Do the math. Only about 2% of the dose is lost during exhalation.(6)

That alone could unlock a historic opportunity.

In addition, as compared to an edible, a 5mg dose from a Rxoid MDI is approximately 2,000% more efficient in delivering leaf into the bloodstream.

“MDIs deliver Active Pharmaceutical Ingredients (API’s) into the blood stream within seconds of inhalation. RTSL’s MDIs are a safe and convenient replacement for vape pens, tanks, and mods, and deliver a 98% bioavailable dose of leaf,” says Sean Berrier, Sr. VP and Co-founder.(7)

RTSL developed this new method of formulating and manufacturing pressurized metered-dose inhalers (pMDI) that contain and properly aerosolize proprietary formula of one or more canna-binoid compounds. So of course, this data could be game-changing news.

Not to mention, RTSL’s nhāler product line is manufactured in full-compliance with GMP.

There’s a perfect storm of factors driving monumental leaf demand…

For one, there’s a substantial amount of support for legalization.

In fact, a Pew Research Center survey found that 67% of the U.S. supports leaf legalization.(5) In addition, a Gallup survey found that 66% of Americans are in favor of legalization. That’s up from just 60% in 2016.(9)

On top of that, 14% of Americans now use leaf products.(10)

Second of all, there’s significant demand for quick relief and higher levels of bioavailability for those seeking relief from medical and mental health issues.

Lastly, the U.S. may be closer to legalization than we realize. After all, according to Reuters, Senators recently unveiled a draft of a bill for legalization.(15)

All as Leaf Has Been Shown to Reduce Issues of Depression, Anxiety, and Stress

According to a study in the Journal of Affective Disorders, leaf can help reduce depression, anxiety, and stress in the short term.(11)

Plus, demand for medical leaf is accelerating because of other reported health benefits, including:

  • Reduction of arthritis pain
  • Reduction of migraines and other headache issues
  • Reduction of inflammation
  • Reduction of sore muscle discomfort
  • Relief from epilepsy and seizures

Rapid Therapeutic Science Laboratories U.S. OTC: (RTSL) Just Filed With The US FDA

Rapid Therapeutic Science Laboratories recently executed two contracts to conduct Phase 1 human clinical trials with its flagship metered dose inhaler (MDI) containing cann-a-bidiol.(12)

RTSL entered into these two contracts in preparation for filing an Investigational New Dr-ug Application (IND) with the U.S. Food and Dr-ug Administration (FDA). (12)

The planned studies will initially focus on the therapeutic benefits of CB relating to depression, anxiety, insomnia, ADHD, and arthritis/chronic pain. Of importance, the studies will measure blood serum levels (pharmacokinetics) to support clinical observations. RTSL will need to file and obtain approval of the IND by the FDA to begin the planned studies.

In addition, according to Dr. Charles Powell, MD, Chief Medical Officer (CMO):

“Based upon my observation from our clinical experience with this product, we think these studies will translate into concrete data that will ultimately result in Phase 2 and 3 studies which will hopefully lead to a fully approved FDA product.”(12)

Rapid Therapeutic Science Laboratories U.S. OTC: (RTSL): Bringing Its Sublingual Spray Products to Market

RTSL is also preparing to launch a marketing and sales campaign of its recently enhanced sublingual spray line (applied via a spray into the mouth).(14)

These sublingual sprays are made using RTSL’s proprietary pharmaceutical-grade isolates in blends for multiple flavors and terpenes. In addition, the sprays are manufactured on the same equipment as RTSL’s metered-dose inhalers (MDI) in the company’s existing ISO Level 6 laboratory. They also fully comply with Good Manufacturing Practice (GMP) standards.

RTSL’s CEO, Donal R. Schmidt, Jr. stated, “Our decision to file an IND application for our flagship MDI containing cann-a-bidiol, as previously announced, requires we remove this MDI product from the market while the application is pending. Nevertheless, this removal will not affect our use of pure pharmaceutical isolates formulas we have developed or our existing aerosol equipment. In fact, in addition to the sublingual sprays we are preparing to market, we are also testing nasal sprays and topical sprays, using our existing equipment and formulas for planned delivery in the fourth quarter.”(14)

In Addition, Rapid Therapeutic Science Laboratories U.S. OTC: (RTSL) Finalized Lab Work on Formulas

The company announced the completion of lab development on three formulas related to the manufacture of pharmaceutical-grade isolates used in both metered-dose inhalers and other aerosol products.

Two of these formulas were developed for cann-a-bidiol, and one for cann-a-bigerol to initially be used in Metered Dose Inhalers (MDI). One formula is expected to be used in the testing of the MDI, which RTSL plans to submit to the FDA in connection with an Investigational New Dr-ug Application (IND).

Rapid Therapeutic Science Laboratories U.S. OTC: (RTSL) Launched New Lifestyle Brand, “nhāler”

Rapid Therapeutic Science Laboratories also announced a relationship with Ezzey Digital Marketing Agency to launch its new proprietary aerosol inhaler and lifestyle brand, nhāler.(16)

Additionally, the company stated that its new ISO 13485 laboratory is ready to begin manufacturing the nhāler brand.

“Our new laboratory allows RTSL to produce up to 2.9 million nhāler and Rxoid™ MDI per year. In addition, as demand increases, we can scale it to double the output with minimal additional personnel or capital outlay in about 9-12 weeks. It also reduces our manufacturing expenses and is a key process to eventual FDA approval of our MDI product line. Certainly, as we produce other aerosolized products in the future such as prescription medication, we will need this lab. I want to congratulate our team for getting the build-out finished on time and under budget.”(13)

The Top Reasons to Have Rapid Therapeutic Science Laboratories U.S. OTC: (RTSL) On Your Radar

  1. Rapid Therapeutic Science Laboratories U.S. OTC: (RTSL) looks well-positioned in a medical leaf market expected to balloon to $35.1 billion in the next five years.(1)
  2. Its products deliver measured amounts of cann-a-bi-noids straight to the systemic blood system through the lungs with a short burst of aerosolized medicine.(2)
  3. Its Rxoid Metered Dose Inhaler is 98% bioavailable.(2)
  4. Compared to edibles, a 5mg dose from a Rxoid MDI is approximately 2,000% more efficient in delivering leaf into the bloodstream.(3)
  5. With more states legalizing the use of green leaf, and speculation of legalization at the federal level, there’s growing excitement.(4)

Source 1: https://bit.ly/3z2bmsQ
Source 2: https://www.biospace.com/article/releases/rapid-therapeutic-announces-major-contract-is-increased-by-150-percent-to-250-000-metered-dose-inhalers-/
Source 3: https://www.rxoid.com/mdi-fda-approve-meter-device/
Source 4: https://bit.ly/3k2KRwX
Source 5: https://pewrsr.ch/3snBfR8
Source 6: http://www.wallstreetresearcher.com/Images/RTSL%20Investor%20Presentation_06102020.pdf
Source 7: https://www.globenewswire.com/fr/news-release/2020/06/22/2051243/0/en/Rapid-Therapeutic-Science-Laboratories-Inc-Highlighted-in-Research-Report-Released-by-Emerald-Equity-Research-LLC.html
Source 8: https://bit.ly/3g8HcMM
Source 9: https://bit.ly/3z0LSfe
Source 10: https://news.gallup.com/poll/263147/americans-say-cbd-products.aspx
Source 11: https://www.sciencedirect.com/science/article/pii/S0165032718303100
Source 12: https://finance.yahoo.com/news/rapid-therapeutic-prepares-file-investigational-110000006.html
Source 13: https://www.globenewswire.com/news-release/2020/08/18/2079793/0/en/Rapid-Therapeutic-Announces-Completion-of-New-ISO-13485-Laboratory.html
Source 14: https://finance.yahoo.com/news/rapid-therapeutic-prepares-bring-sublingual-110000415.html
Source 15: https://reut.rs/3spS7Xn
Source 16: https://www.globenewswire.com/en/news-release/2020/08/06/2074055/0/en/Rapid-Therapeutic-Science-Laboratories-RTSL-Inc-engages-Ezzey-Digital-Marketing-Agency-to-Launch-its-New-Lifestyle-Brand-nh%C4%81ler.html

Legal Disclaimer


This website / media webpage is owned, operated and edited by TD Media LLC. Any wording found on this website / media webpage or disclaimer referencing to “I” or “we” or “our” or “TD Media” refers to TD Media LLC. This website / media webpage is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to market and promote small public companies. By reading our website / media webpage you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our website / media webpage.We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website / media webpage are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our website / media webpage may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. TD Media business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our Websites, Email, SMS, Push Notifications, Influencers, Social Media Postings, Ticker Tags, Press Releases, Online Interviews, Podcasts, Videos, Audio Ads, Banner Ads, Native Ads, Responsive Ads. This compensation is a major conflict of interest in our ability to be unbiased regarding. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, TD Media often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.

INFLUENCER COMPENSATION

Pursuant to an agreement between TD Media LLC and Influencer, TD Media LLC has hired Influencer for a period beginning on 11/30/2020 and ending on 11/30/2020 to publicly disseminate information about (RTSL:US) via digital communications. We have paid this Influencer one thousand three hundred dollars USD.

Pursuant to an agreement between TD Media LLC and Influencer, TD Media LLC has hired Influencer for a period beginning on 12/01/2020 and ending on 12/01/2020 to publicly disseminate information about (RTSL:US) via digital communications. We have paid this Influencer seven hundred fifty dollars USD.

Pursuant to an agreement between TD Media LLC and Influencer, TD Media LLC has hired Influencer for a period beginning on 12/02/2020 and ending on 12/02/2020 to publicly disseminate information about (RTSL:US) via digital communications. We have paid this Influencer one thousand five hundred sixty dollars USD.

Pursuant to an agreement between TD Media LLC and Influencer, TD Media LLC has hired Influencer for a period beginning on 12/02/2020 and ending on 12/02/2020 to publicly disseminate information about (RTSL:US) via digital communications. We have paid this Influencer nine hundred twenty five dollars USD.

Pursuant to an agreement between TD Media LLC and Influencer, TD Media LLC has hired Influencer for a period beginning on 02/04/2021 and ending on 02/05/2021 to publicly disseminate information about (RTSL:US) via digital communications. We have paid this Influencer five hundred dollars USD.

Pursuant to an agreement between TD Media LLC and Influencer, TD Media LLC has hired Influencer for a period beginning on 06/07/2021 and ending on 06/07/2021 to publicly disseminate information about (RTSL:US) via digital communications. We have paid this Influencer five hundred dollars USD.

Pursuant to an agreement between TD Media LLC and Influencer, TD Media LLC has hired Influencer for a period beginning on 06/08/2021 and ending on 06/08/2021 to publicly disseminate information about (RTSL:US) via digital communications. We have paid this Influencer one hundred dollars USD.

COMPENSATION

Pursuant to an agreement between TD Media LLC and Legends Media LLC, TD Media LLC has been hired for a period beginning on 07/08/2020 and ending on 07/15/2020 to publicly disseminate information about (RTSL:US) via digital communications. We have been paid fifteen thousand dollars USD via bank wire transfer.

Pursuant to an agreement between TD Media LLC and Legends Media LLC, TD Media LLC has been hired for a period beginning on 07/31/2020 and ending on 08/07/2020 to publicly disseminate information about (RTSL:US) via digital communications. We have been paid an additional fifteen thousand dollars USD via bank wire transfer. We own zero shares of (RTSL:US). To date we have been paid thirty thousand dollars USD via bank wire transfer. To disseminate information about (RTSL:US) via digital communications.

Pursuant to an agreement between TD Media LLC and Legends Media LLC, TD Media LLC has been hired for a period beginning on 08/10/2020 and ending on 08/14/2020 to publicly disseminate information about (RTSL:US) via digital communications. We have been paid an additional fifteen thousand dollars USD via bank wire transfer. We own zero shares of (RTSL:US). To date we have been paid forty five thousand dollars USD via bank wire transfer. To disseminate information about (RTSL:US) via digital communications.

Pursuant to an agreement between TD Media LLC and Legends Media LLC, TD Media LLC has been hired for a period beginning on 08/17/2020 and ending on 08/21/2020 to publicly disseminate information about (RTSL:US) via digital communications. We have been paid an additional fifteen thousand dollars USD via bank wire transfer. We own zero shares of (RTSL:US). To date we have been paid sixty thousand dollars USD via bank wire transfer. To disseminate information about (RTSL:US) via digital communications.

Pursuant to an agreement between TD Media LLC and Legends Media LLC, TD Media LLC has been hired for a period beginning on 08/24/2020 and ending on 08/28/2020 to publicly disseminate information about (RTSL:US) via digital communications. We have been paid an additional fifteen thousand dollars USD via bank wire transfer. We own zero shares of (RTSL:US). To date we have been paid seventy five thousand dollars USD via bank wire transfer. To disseminate information about (RTSL:US) via digital communications.

Pursuant to an agreement between TD Media LLC and Legends Media LLC, TD Media LLC has been hired for a period beginning on 08/31/2020 and ending on 09/04/2020 to publicly disseminate information about (RTSL:US) via digital communications. We expect to be paid an additional fifteen thousand dollars USD To date we have not been paid. We own zero shares of (RTSL:US).

Pursuant to an agreement between TD Media LLC and Legends Media LLC, TD Media LLC has been hired for a period beginning on 09/08/2020 and ending on 09/14/2020 to publicly disseminate information about (RTSL:US) via digital communications. We have been paid an additional twelve thousand five hundred dollars USD via bank wire transfer. We own zero shares of (RTSL:US). To date we have been paid one hundred two thousand five hundred dollars USD via bank wire transfer. To disseminate information about (RTSL:US) via digital communications.

Pursuant to an agreement between TD Media LLC and Legends Media LLC, TD Media LLC has been hired for a period beginning on 09/15/2020 and ending on 09/21/2020 to publicly disseminate information about (RTSL:US) via digital communications. We have been paid an additional fifteen thousand dollars USD via bank wire transfer. We own zero shares of (RTSL:US). To date we have been paid one hundred seventeen thousand five hundred dollars USD via bank wire transfer. To disseminate information about (RTSL:US) via digital communications.

Pursuant to an agreement between TD Media LLC and Legends Media LLC, TD Media LLC has been hired for a period beginning on 09/28/2020 and ending on 10/02/2020 to publicly disseminate information about (RTSL:US) via digital communications. We have been paid an additional twenty five thousand dollars USD via bank wire transfer. We own zero shares of (RTSL:US). To date we have been paid one hundred forty two thousand five hundred dollars USD via bank wire transfer. To disseminate information about (RTSL:US) via digital communications.

Pursuant to an agreement between TD Media LLC and Legends Media LLC, TD Media LLC has been hired for a period beginning on 10/05/2020 and ending on 10/09/2020 to publicly disseminate information about (RTSL:US) via digital communications. We have been paid an additional twenty thousand dollars USD via bank wire transfer. We own zero shares of (RTSL:US). To date we have been paid one hundred sixty two thousand five hundred dollars USD via bank wire transfer. To disseminate information about (RTSL:US) via digital communications.

Pursuant to an agreement between TD Media LLC and Legends Media LLC, TD Media LLC has been hired for a period beginning on 11/30/2020 and ending on 12/04/2020 to publicly disseminate information about (RTSL:US) via digital communications. We have been paid an additional twenty five thousand dollars USD via bank wire transfer. We own zero shares of (RTSL:US). To date we have been paid one hundred eighty seven thousand five hundred dollars USD via bank wire transfer. To disseminate information about (RTSL:US) via digital communications.

Pursuant to an agreement between TD Media LLC and Legends Media LLC, TD Media LLC has been hired for a period beginning on 12/22/2020 and ending on 12/28/2020 to publicly disseminate information about (RTSL:US) via digital communications. We have been paid an additional twenty five thousand dollars USD via bank wire transfer. We own zero shares of (RTSL:US). To date we have been paid two hundred twelve thousand five hundred dollars USD via bank wire transfer. To disseminate information about (RTSL:US) via digital communications.

Pursuant to an agreement between TD Media LLC and Legends Media LLC, TD Media LLC has been hired for a period beginning on 01/25/2021 and ending on 01/29/2021 to publicly disseminate information about (RTSL:US) via digital communications. We have been paid an additional fifty thousand dollars USD via bank wire transfer. We own zero shares of (RTSL:US). To date we have been paid two hundred sixty two thousand five hundred dollars USD via bank wire transfer. To disseminate information about (RTSL:US) via digital communications.

Pursuant to an agreement between TD Media LLC and Legends Media LLC, TD Media LLC has been hired for a period beginning on 06/01/2021 and ending on 06/11/2021 to publicly disseminate information about (RTSL:US) via digital communications. We have been paid an additional twenty five thousand dollars USD via bank wire transfer. We own zero shares of (RTSL:US). To date we have been paid two hundred eighty seven thousand five hundred dollars USD via bank wire transfer. To disseminate information about (RTSL:US) via digital communications.

(Last updated: 1635286846 unix)

OTC:RTSL
Company Contact

5580 Peterson Ln., Suite 200
Dallas, TX 75240
rtslco.com
(800) 497-6059
[email protected]

What They Do

Rapid Therapeutic Science Laboratories, Inc. holds a sublicense agreement to access to certain technology regarding the RxoidTM metered dose inhaler (TMDI). The TMDI is a medical technology that delivers medication directly to a user’s blood stream through the pulmonary tract. The company was formerly known as Holly Brothers Pictures, Inc. and changed its name to Rapid Therapeutic Science Laboratories, Inc. in January 2020. Rapid Therapeutic Science Laboratories, Inc. was incorporated in 2013 and is based in Dallas, Texas.